Literature DB >> 12367530

Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Hilal A Lashuel1, Benjamin M Petre, Joseph Wall, Martha Simon, Richard J Nowak, Thomas Walz, Peter T Lansbury.   

Abstract

Two mutations in the alpha-synuclein gene (A30P and A53T) have been linked to autosomal dominant early-onset Parkinson's disease (PD). Both mutations promote the formation of transient protofibrils (prefibrillar oligomers), suggesting that protofibrils are linked to cytotoxicity. In this work, the effect of these mutations on the structure of alpha-synuclein oligomers was investigated using electron microscopy and digital image processing. The PD-linked mutations (A30P and A53T) were observed to affect both the morphology and the size distribution of alpha-synuclein protofibrils (measured by analytical ultracentrifugation and scanning transmission electron microscopy). The A30P variant was observed to promote the formation of annular, pore-like protofibrils, whereas A53T promotes formation of annular and tubular protofibrillar structures. Wild-type alpha-synuclein also formed annular protofibrils, but only after extended incubation. The formation of pore-like oligomeric structures may explain the membrane permeabilization activity of alpha-synuclein protofibrils. These structures may contribute to the pathogenesis of PD.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12367530     DOI: 10.1016/s0022-2836(02)00735-0

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  249 in total

1.  Dynamic imaging by fluorescence correlation spectroscopy identifies diverse populations of polyglutamine oligomers formed in vivo.

Authors:  Monica Beam; M Catarina Silva; Richard I Morimoto
Journal:  J Biol Chem       Date:  2012-06-05       Impact factor: 5.157

2.  CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease.

Authors:  Michael R Sierks; Gaurav Chatterjee; Claire McGraw; Srinath Kasturirangan; Philip Schulz; Shalini Prasad
Journal:  Integr Biol (Camb)       Date:  2011-11-10       Impact factor: 2.192

3.  Interaction of tau protein with model lipid membranes induces tau structural compaction and membrane disruption.

Authors:  Emmalee M Jones; Manish Dubey; Phillip J Camp; Briana C Vernon; Jacek Biernat; Eckhard Mandelkow; Jaroslaw Majewski; Eva Y Chi
Journal:  Biochemistry       Date:  2012-03-14       Impact factor: 3.162

4.  Kinetic control of dimer structure formation in amyloid fibrillogenesis.

Authors:  Wonmuk Hwang; Shuguang Zhang; Roger D Kamm; Martin Karplus
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

5.  Lentivirus mediated delivery of neurosin promotes clearance of wild-type α-synuclein and reduces the pathology in an α-synuclein model of LBD.

Authors:  Brian Spencer; Sarah Michael; Jay Shen; Kori Kosberg; Edward Rockenstein; Christina Patrick; Anthony Adame; Eliezer Masliah
Journal:  Mol Ther       Date:  2012-04-17       Impact factor: 11.454

6.  Microcin amyloid fibrils A are reservoir of toxic oligomeric species.

Authors:  Mohammad Shahnawaz; Claudio Soto
Journal:  J Biol Chem       Date:  2012-02-15       Impact factor: 5.157

7.  Assessing the subcellular dynamics of alpha-synuclein using photoactivation microscopy.

Authors:  Susana Gonçalves; Tiago Fleming Outeiro
Journal:  Mol Neurobiol       Date:  2013-02-08       Impact factor: 5.590

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

9.  Quantification of alpha-synuclein binding to lipid vesicles using fluorescence correlation spectroscopy.

Authors:  Elizabeth Rhoades; Trudy F Ramlall; Watt W Webb; David Eliezer
Journal:  Biophys J       Date:  2006-03-31       Impact factor: 4.033

10.  Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Authors:  Markus Mandler; Elvira Valera; Edward Rockenstein; Harald Weninger; Christina Patrick; Anthony Adame; Radmila Santic; Stefanie Meindl; Benjamin Vigl; Oskar Smrzka; Achim Schneeberger; Frank Mattner; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2014-02-14       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.